Evidence map›Paper›PMID 31468122›Full record

ArticleJournal of cancer research and clinical oncology2019

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.

Niels Smedegaard Andersen, Martin Bornhäuser, Martin Gramatzki, Peter Dreger, Antonin Vitek, Michal Karas, Mauricette Michallet, Carol Moreno, Michel van Gelder, Anja Henseler and 5 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 6 countries.

Niels Smedegaard AndersenBMT Unit Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Martin BornhäuserMedical Department I, University Hospital Dresden, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
Martin GramatzkiDivision of Stem Cell Transplantation and Immunotherapy, University Hospital Schleswig-Holstein, Kiel, Germany.
Peter DregerMedizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany.
Antonin VitekDepartment of Haematology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Michal KarasDepartment of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic.
Mauricette MichalletCentre Hospitalier Lyon-Sud-Hématologie, Lyon, France.
Carol MorenoHematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Michel van GelderDepartment of Internal Medicine Hematology, University Hospital Maastricht, Maastricht, The Netherlands.
Anja HenselerDepartment of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Liesbeth C de WreedeDepartment of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Stefan SchönlandMedizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany.
Nicolaus KrögerBone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany.
Johannes ScheteligMedical Department I, University Hospital Dresden, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany. Johannes.schetelig@uniklinikum-dresden.de.ORCID http://orcid.org/0000-0002-2780-2981
CLL subcommittee, Chronic Malignancies Working Party
Deutsche Knochenmarkspenderdatei · DEHeidelberg University · DELeiden University Medical Center · NLCharles University · CZHôpital Lyon Sud · FRHospital de Sant Pau · ESInstitute of Haematology and Blood Transfusion · CZMaastricht University Medical Centre · NLRigshospitalet · DKUniversität Hamburg · DEUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe optimal dose intensity for conditioning prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) is unknown.

methodsWe retrospectively compared outcomes of patients who received a first alloHCST after non-myeloablative (NMA) and reduced intensity conditioning (RIC). Data of 432 patients with a median age of 55 years were included, of which 86 patients underwent NMA and 346 RIC.

resultsThe median follow-up after alloHSCT was 4.3 years. Compared to the RIC group, more NMA patients had purine-analog-sensitive disease, were in complete remission and received matched related donor transplantation. After RIC, the probabilities for 5-year OS, EFS, CIR, and NRM were 46%, 38%, 28%, and 35% and after NMA the respective probabilities were 52%, 43%, 25%, and 32%. In multivariate analysis, remission status prior to conditioning but not RIC versus NMA conditioning had a significant impact on CIR, EFS, and OS.

conclusionPresumed higher anti-leukemic activity of RIC versus NMA conditioning did not translate into better outcomes after alloHSCT, but better remission status prior to conditioning did. Effective pathway inhibitor-based salvage therapies combined with NMA conditioning might thus represent the most attractive contemporary approach for alloHSCT for patients with CLL.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBusulfanCombined Modality TherapyCyclophosphamideFemaleFollow-Up StudiesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansIncidenceLeukemia, Lymphocytic, Chronic, B-CellMaleMelphalanMiddle AgedBusulfanCyclophosphamideMelphalanAllogeneic hematopoietic stem cell transplantationNonmyeloablative/reduced intensity conditioningRelapsed/refractory chronic lymphocytic leukemia

Identifiers

PMID31468122
PMCPMC11810217
OpenAlexW2970425979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.